A tale of two IPOs (plus one): Cabaletta prices well below range for $75M while Phathom bags $182M

When Cabaletta Bio and Phathom Pharmaceuticals penciled in $100 million IPOs alongside 4D Molecular Therapeutics back in the beginning of October, they appeared to be riding on a wave of positive sentiments in the public markets — albeit against some chatter in the background about how long the buoyant conditions will last.